Endo, Novartis begin Voltaren gel licensing deal

Share this article:
Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.

Endo said it expects to commercialize Voltaren Gel initially using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full physician launch in late May, with an additional 275 contract sales representatives targeting primary care physicians who prescribe NSAIDs and Cox-2s.
Voltaren Gel received FDA approval in October 2007, being granted marketing exclusivity in the US as a prescription medicine at least until October 2010.

Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million.

Under the terms of the five-year agreement with Novartis, Endo will make an upfront cash payment of $85 million.

Novartis is also eligible to receive a one-time milestone payment of $25 million if annual sales exceed $300 million. Under the deal, Novartis will receive royalties on the net sales of Voltaren Gel in the US and will supply this product to Endo.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.